The New England Journal of Medicine has published the results from a rigorous randomized controlled trial in Kenya. Keheala, a digital health startup, helped reduce the unsuccessful treatment outcomes for tuberculosis (TB) patients by two-thirds.
Read MoreKeheala selected by World Bank Group and Brazilian healthcare providers for piloting opportunity.
Read MoreKeheala joins global network of startups
Read MoreKeheala's innovation was recently recognized with awards from Teva Pharmaceuticals and Nefesh B'Nefesh
Read MoreThe U.S. Agency for International Development (USAID) through the Global Development Lab's Development Innovation Ventures (DIV) program announced Keheala as one of 18 recent grantees. While the majority of grantees are new to USAID, this is the second award Keheala has received from the development agency to improve tuberculosis treatment success rates in Kenya.
Read More